We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+29.97%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$752M
AUM Growth
+$105M
Cap. Flow
-$17.7M
Cap. Flow %
-2.36%
Top 10 Hldgs %
46.3%
Holding
87
New
16
Increased
20
Reduced
11
Closed
7

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$16.7M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$16M
3
DVAX
Dynavax Technologies
DVAX
+$10.9M
4
NVRO
NEVRO CORP.
NVRO
+$10.2M
5
CHRS icon
Coherus Oncology
CHRS
+$8.85M

Top Sells

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$39.5M
2
BMY icon
Bristol-Myers Squibb
BMY
+$29.6M
3
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$28.1M
4
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$27.1M
5
CMRX
Chimerix, Inc.
CMRX
+$8.65M

Sector Composition

Rank Sector Weight
1 Healthcare 88.18%
2 Miscellaneous 11.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLLS
76
Cellectis
CLLS
$140M
$408K 0.05%
11,300
-13,700
-55% -$481K
AGTC
77
DELISTED
Applied Genetic Technologies Corporation
AGTC
$262K 0.03%
17,110
-8,900
-34% -$171K
AKTX
78
Akari Therapeutics
AKTX
$20M
$166K 0.02%
36
– –
BMY icon
79
Bristol-Myers Squibb
BMY
$130B
– –
-459,000
Closed -$29.6M
PBYI icon
80
Puma Biotechnology
PBYI
$479M
– –
-167,300
Closed -$39.5M
PTCT icon
81
PTC Therapeutics
PTCT
$5.6B
– –
-8,500
Closed -$517K
SAGE
82
DELISTED
Sage Therapeutics
SAGE
– –
-850
Closed -$43K
CMRX
83
DELISTED
Chimerix, Inc.
CMRX
– –
-229,500
Closed -$8.65M
BLCM
84
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-5,100
Closed -$1.18M
GEVA
85
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
– –
-42,500
Closed -$4.14M
1 2 3
4

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q2 2015 Portfolio in Review

As of Q2 2015, Cormorant Asset Management held 87 positions worth $752M, up 16% from $647M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Cormorant Asset Management's Q2 2015 filing shows 16 new, 20 increased, 11 reduced and 7 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 140,000 shares worth $16.8M. The largest sale was Puma Biotechnology, an estimated $39.5M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 85% a quarter earlier, followed by Miscellaneous.

  • Cormorant Asset Management's largest Q2 2015 buy was Alnylam Pharmaceuticals: 140,000 shares worth $16.8M.
  • Cormorant Asset Management added most to Alder Biopharmaceuticals in Q2 2015, an estimated $16M increase.
  • Cormorant Asset Management's biggest Q2 2015 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $28.1M.
  • Cormorant Asset Management fully exited Puma Biotechnology in Q2 2015, selling an estimated $39.5M.
  • Cormorant Asset Management's ten largest holdings make up 46% of its $752M portfolio in Q2 2015.
  • Cormorant Asset Management opened 16 new positions and closed 7 in Q2 2015.
  • Cormorant Asset Management's portfolio value rose 16% quarter-over-quarter to $752M.

Based on Cormorant Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.